 (9CI) Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C146H239N47O44S3 |
| Molecular Weight | 3452.94335999998 |
| Exact Mass | 3450.71 |
| CAS # | 133448-20-1 |
| Related CAS # | Brain Natriuretic Peptide (1-32), rat acetate |
| PubChem CID | 71308564 |
| Appearance | Typically exists as solid at room temperature |
| LogP | -17.6 |
| Hydrogen Bond Donor Count | 54 |
| Hydrogen Bond Acceptor Count | 54 |
| Rotatable Bond Count | 88 |
| Heavy Atom Count | 240 |
| Complexity | 7870 |
| Defined Atom Stereocenter Count | 30 |
| SMILES | CC[C@@H]([C@H]1C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)CC(C)C)=O)CCCNC(N)=N)=O)CC(C)C)=O)=O)CC(O)=O)=O)CSSC[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N)CC(N)=O)=O)CO)=O)CCCCN)=O)CCSC)=O)C)=O)CC3=CN=CN3)=O)CO)=O)CO)=O)CO)=O)C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1)=O)CCCNC(N)=N)=O)CC(O)=O)=O)[C@H](CC)C)=O)CCCCN)=O)CCC(N)=O)=O)=O)CC4=CC=CC=C4)=O)=O)=O)CC(C)C)=O)CCCNC(N)=N)=O)CO)=O)C(C)C)=O)C)=O)=O)C |
| InChi Key | CKSKSHHAEYGHSB-LBCJMRPYSA-N |
| InChi Code | InChI=1S/C146H239N47O44S3/c1-16-75(11)114-140(233)165-59-107(201)167-77(13)117(210)191-113(74(9)10)141(234)189-102(67-198)134(227)176-86(38-29-46-160-145(154)155)124(217)179-90(49-71(3)4)119(212)162-62-110(204)171-103(138(231)182-95(56-111(205)206)121(214)164-61-109(203)170-91(50-72(5)6)129(222)173-85(37-28-45-159-144(152)153)125(218)180-92(51-73(7)8)130(223)184-97(143(236)237)53-80-33-22-19-23-34-80)68-239-240-69-104(139(232)181-93(52-79-31-20-18-21-32-79)120(213)163-60-108(202)169-88(40-41-105(150)199)126(219)172-84(36-25-27-44-148)127(220)193-115(76(12)17-2)142(235)183-96(57-112(207)208)132(225)174-87(128(221)192-114)39-30-47-161-146(156)157)190-137(230)101(66-197)188-136(229)100(65-196)187-135(228)99(64-195)186-131(224)94(54-81-58-158-70-166-81)178-116(209)78(14)168-122(215)89(42-48-238-15)177-123(216)83(35-24-26-43-147)175-133(226)98(63-194)185-118(211)82(149)55-106(151)200/h18-23,31-34,58,70-78,82-104,113-115,194-198H,16-17,24-30,35-57,59-69,147-149H2,1-15H3,(H2,150,199)(H2,151,200)(H,158,166)(H,162,212)(H,163,213)(H,164,214)(H,165,233)(H,167,201)(H,168,215)(H,169,202)(H,170,203)(H,171,204)(H,172,219)(H,173,222)(H,174,225)(H,175,226)(H,176,227)(H,177,216)(H,178,209)(H,179,217)(H,180,218)(H,181,232)(H,182,231)(H,183,235)(H,184,223)(H,185,211)(H,186,224)(H,187,228)(H,188,229)(H,189,234)(H,190,230)(H,191,210)(H,192,221)(H,193,220)(H,205,206)(H,207,208)(H,236,237)(H4,152,153,159)(H4,154,155,160)(H4,156,157,161)/t75-,76-,77-,78-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,113-,114-,115-/m0/s1 |
| Chemical Name | (3S)-3-[[(4R,10S,13S,16S,19S,22S,28S,31S,34S,37S,40S,43S,49S,52R)-40-(4-aminobutyl)-52-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-43-(3-amino-3-oxopropyl)-49-benzyl-28,37-bis[(2S)-butan-2-yl]-13,31-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16-(hydroxymethyl)-22-methyl-10-(2-methylpropyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-19-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]-4-[[2-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-4-oxobutanoic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets |
Natriuretic peptide receptor (likely NPR-A or NPR-B, specific subtype not specified) [2] |
| ln Vitro | BNP, or natriuretic peptide, lowers blood pressure and ventricular fibrosis to counteract cardiac stress. The 45-residue amino-truncated version of native rat BNP is known as rBNP (1-32) [1]. The brain contains three natriuretic peptides that help regulate body fluid homeostasis: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). These peptides are concentrated in the anteroventral region of the third ventricle. Through their receptors NPR-A and NPR-B, ANP(1-28), BNP(1-32), and CNP(1-32) contribute to the regulation of salt and water balance in the mammalian brain [2]. |
| ln Vivo | In conscious spontaneously hypertensive rats (SHR) and conscious cynomolgus monkeys treated with vehicle or selective neutral endopeptidase, the antihypertensive, natriuretic, and cyclic GMP effects of several brain natriuretic peptides (BNP) were evaluate. The atrial natriuretic peptide (ANP) 99-126 inhibitor SQ 28603 was used to compare the responses. The natriuretic and circulatory GMP responses to 3 nmol/kg iv rat BNP (1-32) in conscious SHR were considerably enhanced at 100 mumol/kg iv 28,603 Sq.ft. and were greater than rat ANP 99-126 larger than pig BNP-26. Neither human BNP-32 nor vehicle or SQ 28,603 were effective in treating SHR. On the other hand, 3 nmol/kg iv higher Mouse BNP (1-32) lowers mean arterial pressure without affecting renal function, while 1 nmol/kg iv human BNP (1-32) stimulates the kidneys and inhibits responses in conscious monkeys with effects greater than or comparable to those triggered by human ANP 99-126 [3]. |
| Cell Assay |
An ex vivo brain slice model was used to assess cellular response. Rat brain slices (400 μm thick) containing the ventricles were prepared. Slices were superfused with oxygenated Krebs buffer containing phosphodiesterase and protease inhibitors. After equilibration, slices were stimulated by adding brain natriuretic peptide-(1-32) (BNP) (concentrations tested: 100 nM) to the superfusion buffer for 10 minutes. The stimulation was terminated by fixing the slices. The fixed slices were then sectioned and subjected to cyclic GMP immunohistochemistry using a specific anti-cyclic GMP antibody to visualize increases in intracellular cyclic GMP levels in ependymal cells lining the ventricles. [2] |
| References |
[1]. Human B-type natriuretic peptide is not degraded by meprin A. Biochem Pharmacol. 2010 Oct 1;80(7):1007-11. [2]. Natriuretic peptides, but not nitric oxide donors, elevate levels of cytosolic guanosine 3',5'-cyclic monophosphate in ependymal cells ex vivo. Neurosci Lett. 2006 Jan 16;392(3):187-92. [3]. Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase3.4.24.11, in monkeys and rats. J Pharmacol Exp Ther. 1992 Jul;262(1):60-70. |
| Additional Infomation |
Brain natriuretic peptide (BNP) is mentioned as one of the natriuretic peptides (alongside ANP and CNP) present in the brain, concentrated in the anteroventral area of the third cerebral ventricle, and involved in regulating body fluid homeostasis. [2] In the ex vivo brain slice system, brain natriuretic peptide-(1-32) (BNP) at a concentration of 100 nM was able to increase the level of cytosolic cyclic GMP specifically in the polyciliated ependymal cells lining the cerebral ventricles, as detected by cyclic GMP immunohistochemistry. This effect was similar to that of ANP and CNP, but contrasted with nitric oxide donors, which increased cyclic GMP in the brain parenchyma but not in the ependymal cells. [2] |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2896 mL | 1.4480 mL | 2.8961 mL | |
| 5 mM | 0.0579 mL | 0.2896 mL | 0.5792 mL | |
| 10 mM | 0.0290 mL | 0.1448 mL | 0.2896 mL |